Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

The Independent UK

Weight-loss jabs linked to hundreds of cases of life-threatening illness and 10 deaths

Weight-loss jabs linked to hundreds of cases of life-threatening illness and 10 deaths

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking them, figures from the UK’s medicines regulator reveal

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

‘I was diagnosed with potentially deadly condition after taking weight-loss jab now offered on NHS’

Exclusive: Julie Bishop lost two-and-a-half stone in eight weeks by taking Mounjaro before she was sent to hospital with pancreatitis and told to stop taking the weight-loss jab

The Independent UK

Hundreds of weight loss and diabetes jab users report pancreas problems

UK health officials launch study into side-effects of weight loss drugs after increased reports of acute pancreatitis

The Guardian - UK

Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.

Evening Standard

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

inkl

Read news from The Economist, FT, and more,
with one subscription

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Is Eli Lilly and Company Stock Underperforming the Dow?

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

Two checkered names from diverse industries are looking to bolster their manufacturing capabilities in the U.S. Here's how they stack up as investment ideas.

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

Ozempic in a pill? New oral drug may work as well as Ozempic-style injectables

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like Ozempic.

Get all your
news in one place.

100's of premium titles.
One news app.

Experimental daily pill found to aid weight loss in what could be alternative to jabs like Ozempic

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Experimental Drug Shows Promise In Eliminating Hard-To-Treat Deadly Cholesterol

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

The Independent UK

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

Price Targets Show These 3 Stocks Near the $1 Trillion Mark

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

The Times of India

Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects

Eli Lilly's blockbuster drug 'Mounjaro' was launched in India on Thursday. The pharma manufacturer said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). The company said it has introduced Mounjaro in a…

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

1 … 6 7 8 9

People

190,001 stories

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

The New York Times

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Executive Order

Alzheimer Disease

Places

374,603 stories

139,166 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play